Publication Name	World Journal of Gastroenterology
Manuscript ID	10905
Country	Italy

Received	2014-04-25 09:21
Peer-Review Started	2014-04-25 21:12
First Decision by Editorial Office Director
Return for Revision	2014-06-05 19:39
Revised	2014-06-19 05:38
Publication Fee Transferred
Second Decision by Editor	2014-07-30 10:07
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-07-30 10:19
Articles in Press	2014-07-30 10:45
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-13 19:34
Publish the Manuscript Online	2014-12-02 10:46

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Clinical Trials Study
Article Title	Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women
Manuscript Source	Unsolicited Manuscript
All Author List	Veronica Bernabucci, Alessia Ciancio, Salvatore Petta, Aimilia Karampatou, Laura Turco, Silvia Strona, Rosina Critelli, Paola Todesca, Caterina Cerami, Caterina Sagnelli, Mario Rizzetto, Calogero Cammà and Erica Villa
Funding Agency and Grant Number	Funding Agency Grant Number Schering-Plough (now Merck)
Corresponding Author	Erica Villa, Professor, Division of Gastroenterology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, via del Pozzo 71, 41124 Modena, Italy. erica.villa@unimore.it
Key Words	Hepatitis C virus treatment; Pegylated Interferon; Viral Hepatitis; Menopause; Genotype 1
Core Tip	After menopause liver disease in hepatitis C virus-positive women becomes rapidly progressive, severe fibrosis develops, and response to antiviral therapy becomes very low. Re-treatment with standard dual therapy in previous failures of Peginterferon-??+ Ribavirin (PEG-IFN?/RBV) treatments does not achieve more than 5%-10% sustained virological response (SVR). The addition of Boceprevir to PEG-IFN?/RBV in menopausal women with HCV-1 genotype infection, who had previously failed dual antiviral therapy, determined a striking improvement of SVR. More than 45% of women re-treated with triple therapy achieved SVR, with few side effects and good tolerability. Response after 4 wk of Boceprevir was the only independent factor predicting SVR.
Publish Date	2014-12-02 10:46
Citation	Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World J Gastroenterol 2014; 20(44): 16726-16733
URL	http://www.wjgnet.com/1007-9327/full/v20/i44/16726.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i44.16726

Full Article (PDF)	WJG-20-16726.pdf
Full Article (Word)	WJG-20-16726.doc
Manuscript File	10905-Review.docx
Answering Reviewers	10905-Answering Reviewers.pdf
Copyright License Agreement	10905-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140425005605.pdf
Non-Native Speakers of English Editing Certificate	10905-Language certificate.pdf
Peer-review Report	10905-Peer review.pdf
Scientific Misconduct Check	10905-CorssCheck.jpg